What is VCNX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VCNX?

P/E (TTM) is n/a and 52-week range is $0.31 to $1.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VCNX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VCNX?

The company profile lists revenue (TTM) near $500K, net income (TTM) near $-1.55B, EPS (TTM) near $-9.91 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vaccinex Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rochester, New York, US, 2.7M shares outstanding, ISIN US9186403013 when available from company profile and filing metadata.

Vaccinex Inc

$VCNX

Health Care · Biotechnology

IR Run Scenarios

$1.14

-0.87%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 23 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. The company also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Employees

Website

www.vaccinex.com/

IPO

2018-08-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)